Study Reveals No Dementia Benefit of β3 Agonists Over Anticholinergics

A recent cohort study involving over 830,000 adults indicates that β3 agonists do not reduce dementia risk compared to anticholinergics in overactive bladder treatments.

A
Aapla Nagpur Desk
16 Nov 2026, 9:16 PM IST · 2 min read
Source: AJMC
Study Reveals No Dementia Benefit of β3 Agonists Over Anticholinergics
KEY TAKEAWAYS
1

830,393 adults were analyzed for dementia risk related to OAB treatments.

2

High-risk anticholinergics showed a slightly lower dementia hazard than β3 agonists.

3

No significant difference in dementia incidence was found between drug classes.

A comprehensive study conducted by researchers at University Hospitals Cleveland Medical Center and Oberlin College has found that β3 agonists do not offer a dementia risk advantage over anticholinergics in treating overactive bladder (OAB). The analysis, which utilized electronic health record data from 2012 to 2025, included 830,393 adults aged 40 to 90 who began treatment within a year of their OAB diagnosis and had no prior history of dementia. The median age of participants was 67, with a significant majority being women.

The study categorized patients based on the first medication prescribed, revealing that 68.9% were given high-risk anticholinergics, 6.0% low-risk anticholinergics, and 25.1% β3 agonists. Out of the total cohort, 7.8% developed dementia, identified through diagnosis codes or prescriptions for dementia medications. The median follow-up period varied, with β3 agonist users averaging 1,046 days and high-risk anticholinergic users averaging 1,568 days.

After adjusting for patient characteristics, the findings indicated that high-risk anticholinergics had a lower hazard ratio (HR) for dementia compared to β3 agonists (HR 0.90), while low-risk anticholinergics showed no significant difference (HR 0.97). The weighted 10-year dementia risk was calculated to be 20.0% for β3 agonists, 19.0% for low-risk anticholinergics, and 18.1% for high-risk anticholinergics, suggesting that the perceived cognitive safety of β3 agonists may not be substantiated.

The implications of this study are significant for clinical practice, as the assumption that β3 agonists are safer for cognitive health may need reevaluation. The results challenge the trend of prescribing β3 agonists over anticholinergics due to concerns about dementia risk. Furthermore, the authors noted that the small difference observed could be attributed to residual channeling bias, where clinicians may preferentially prescribe β3 agonists to older adults or those with higher cognitive risk.

Looking ahead, this research underscores the need for further studies to explore the relationship between OAB treatments and dementia risk. The authors caution that their retrospective design limits definitive conclusions about the safety of these medication classes, but they emphasize that any class-specific contribution to dementia risk appears minimal. Future investigations could help clarify these findings and inform treatment guidelines for OAB management.

💬What did you think of this story?What did you think?

Read Next